KOREA WHO

Ryu Joon-soo is the CEO of ISU Abxis.

He has presented a new drug development roadmap for antibody therapeutics, setting a goal of achieving a “big-deal” level technology export within three years.

He was born on January 14, 1972.

He graduated from the Department of Food Science and Biotechnology at Seoul National University and earned both his master’s and doctoral degrees in Biological Sciences from KAIST.

He completed an MBA program at the Tuck School of Business at Dartmouth College in the United States.

He began his career as a drug developer at the ISU Abxis R&D Center, later gaining experience in bio business management and corporate strategy by handling product portfolio management at Hanwha Group’s Bio Division and pharmaceutical management strategy consulting at IMS Consulting Group Korea.

After working at Mundipharma Korea, a global pharmaceutical company, he served as a senior managing director at GC Pharma and was appointed CEO of Kyne Science in 2019.

He then moved to Dong-A ST as Executive Director in charge of R&D Strategy and returned to ISU Abxis as CEO in March 2025.

He has overseen business management and corporate strategy across a wide range of bio organizations, from biotech ventures to traditional domestic pharmaceutical companies and multinational corporations.

#RyuJoonsoo #ISUAbxis #biotech #antibody #drugdevelopment #pharmaceutical #KoreaBiotech #lifescience #MBA #businessstrategy